KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Other Operating Expenses (2018 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Other Operating Expenses for 5 consecutive years, with -$6.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Operating Expenses fell 47.36% to -$6.7 million in Q3 2025 year-over-year; TTM through Dec 2025 was -$18.3 million, a 11.6% increase, with the full-year FY2024 number at -$20.7 million, down 43.69% from a year prior.
  • Other Operating Expenses was -$6.7 million for Q3 2025 at Xenon Pharmaceuticals, down from -$6.0 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $53.3 million in Q4 2024 to a low of -$63.7 million in Q1 2024.